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Abstract
Background Late-onset Pompe disease (LOPD) is a genetic disorder characterized by progressive degeneration of the skeletal
muscles produced by a deficiency of the enzyme acid alpha-glucosidase. Enzymatic replacement therapy with recombinant
human alpha-glucosidase seems to reduce the progression of the disease; although at the moment, it is not completely clear
to what extent. Quantitative muscle magnetic resonance imaging (qMRI) is a good biomarker for the follow-up of fat replace-
ment in neuromuscular disorders. The aim of this study was to describe the changes observed in fat replacement in skeletal
muscles using qMRI in a cohort of LOPD patients followed prospectively.
Methods A total of 36 LOPD patients were seen once every year for 4 years. qMRI, several muscle function tests, spirometry,
activities of daily living scales, and quality-of-life scales were performed on each visit. Muscle MRI consisted of two-point Dixon
studies of the trunk and thigh muscles. Computer analysis of the images provided the percentage of muscle degenerated and
replaced by fat in every muscle (known as fat fraction). Longitudinal analysis of the measures was performed using linear
mixed models applying the Greenhouse–Geisser test.
Results We detected a statistically significant and continuous increase in mean thigh fat fraction both in treated (+5.8% in 3
years) and in pre-symptomatic patients (+2.6% in 3years) (Greenhouse–Geisser p< 0.05). As an average, fat fraction increased
by 1.9% per year in treated patients, compared with 0.8% in pre-symptomatic patients. Fat fraction significantly increased in
every muscle of the thighs. We observed a significant correlation between changes observed in fat fraction in qMRI and
changes observed in the results of the muscle function tests performed. Moreover, we identified that muscle performance
and mean thigh fat fraction at baseline visit were independent parameters influencing fat fraction progression over 4 years
(analysis of covariance, p < 0.05).
Conclusions Our study identifies that skeletal muscle fat fraction continues to increase in patients with LOPD despite the
treatment with enzymatic replacement therapy. These results suggest that the process of muscle degeneration is not stopped
by the treatment and could impact muscle function over the years. Hereby, we show that fat fraction along with muscle func-
tion tests can be considered a good outcome measures for clinical trials in LOPD patients.
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Introduction
Pompe disease is a rare autosomal recessive disorder
produced by mutations in the GAA gene, which encodes the
enzyme acid alpha-glucosidase. This enzyme metabolizes gly-
cogen to glucose inside lysosomes1. Consequently, mutations
in the GAA gene lead to glycogen accumulation in numerous
tissues, but clinical symptoms are primarily because of
cardiac and skeletal muscle involvement.2
Pompe disease has two distinct phenotypes. The classic in-
fantile phenotype is characterized by the onset of symptoms
in the first months of life, with muscle weakness, hypertro-
phic cardiomyopathy, and respiratory insufficiency.3 Patients
die early if they are not treated.4 In contrast, late-onset
Pompe disease (LOPD) is more heterogeneous in its clinical
presentation.5,6 Patients may present with asymptomatic
hyperckemia or develop a slowly progressive weakness in-
volving respiratory, axial, and limb muscles.7,8
Enzymatic replacement therapy (ERT) with alglucosidase
alfa (Myozyme®, Sanofi-Genzyme, Cambridge, MA, USA) is ac-
cepted as the standard treatment for Pompe disease. Several
open label studies have demonstrated its efficacy in maintain-
ing muscle function in LOPD since the original clinical trial was
published in 2010.9–11 However, a recent single-centre follow-
up study suggests that the initial improvement lasts for up to
2 or 3 years and is followed by a progressive deterioration in
skeletal and respiratory muscle function.12 Clinical trials with
new therapeutic strategies, including improved enzymes or
genetic therapies, are being designed and will probably start
in the next few years.13,14 These trials will probably rely on
functional outcome measures to demonstrate their efficacy.
The changes that can be found in common muscle function
tests in LOPD patients treated with Myozime® for several
years have not been clearly established. Functional tests have
the disadvantage of being subject to motivation, are influ-
enced by several external factors, and often display limited
interoperator reproducibility.15 Moreover, the process of
muscle degeneration and fatty substitution may have started
without yet influencing the results of the muscle function
tests. Therefore, there is a need for robust biomarkers sensi-
tive to disease progression and treatment efficacy.16
In recent years, muscle magnetic resonance imaging (MRI)
has been proposed as a valuable tool for both the diagnosis
and follow-up of patients with muscle disorders. The identifi-
cation of muscles replaced by fat can be easily assessed using
T1-weighted sequences, which is helpful in the diagnosis pro-
cess of patients.17 However, patient follow-up requires a
more specific technique, such as the Dixon MRI sequence,
which is able to quantify the amount of fat present in an area
of skeletal muscle of interest.18 This test is useful in natural
history studies or clinical trials. In the case of Pompe disease,
two studies applied Dixon to a large cohort of LOPD patients
and in both cases demonstrated that the sequence is able to
identify an increase in fat replacement in skeletal muscles
over a 1 year period.19,20 However, it is not known if the rate
of progression of fat replacement in LOPD is stable over time
or which clinical and/or demographic factors can influence
this progression.
The aim of our study was to describe the changes observed
in fat replacement in skeletal muscles over a period of 4 years
in a long cohort of LOPD patients.
Methods
Study design and participants
This study was a prospective, open-label cohort study
involving 36 patients with a confirmed diagnosis of LOPD
performed at the Hospital de la Santa Creu i Sant Pau (HSCSP)
in Barcelona, from December 2013 to June 2018. All patients
were evaluated once every 12 months (±2 months) for a total
of four visits. At each visit, we performed muscle function
tests, spirometry, quality-of-life scales, and quantitative
muscle MRI. The study was registered in ClinicalTrials.gov
with the identifier NCT01914536. The HSCSP ethics commit-
tee approved the study, and all participants signed an
informed consent form. All study procedures were performed
in accordance with Spanish regulations.
Inclusion criteria for the study were (i) diagnosis of LOPD
based on recommendations proposed by the European
Pompe Consortium, reduced enzymatic activity in leukocytes,
fibroblasts, or skeletal muscle and/or the presence of two
mutations in the GAA gene21; (ii) no contraindications to
MRI; and (iii) willingness to complete all muscle function
tests, respiratory assessment, and patient-reported out-
comes measures. We included in the study both patients with
skeletal muscle weakness and respiratory involvement and
patients without symptoms.
All patients were studied by three physiotherapists (I.B., I.
P., and E.M) with considerable experience in neuromuscular
disorders at HSCSP. All patients were evaluated by the same
physiotherapist throughout the whole study. The physiother-
apists evaluated muscle function using the following tests:
the 6 minute walking test, time to walk 10 m, timed up-
and-go test, time to climb up and down four steps, and the
Motor Function Measure 20-item scale (MFM-20). All timed
tests were performed asking the patient to not use aids for
walking. Muscle strength was studied using both the Medical
Research Council (MRC) scale and hand-held myometry. Daily
life activities were studied using the activity limitations scale
for patients with upper and/or lower limb impairments, and
quality of life was analysed using both the Individualized
Neuromuscular Quality of Life Questionnaire and the Short
Form 36 questionnaire. We obtained forced vital capacity,
both seated and lying down, using the Carefusion Microlab
ML 3500 MK8 spirometer (Carefusion, Yorba Linda, CA, USA).
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Muscle imaging
All patients were examined in a 1.5 magnetic resonance
system (1.5 Achieva dStream; Philips, Eindhoven, NL) at
HSCSP as previously described.22 We used the same position-
ing protocol for all patients: a supine position with the legs
stretched out.
Axial 3D Dixon Fast Field Echo was performed on the pelvis
and thighs by using a thirty-two body coil, with the following
parameters: the repetition time (TR) the echo time (TE) =
5.78/1.8, 4 m, flip angle = 15°, field of view = 520 × 340 ×
300mm, voxel size = 1 × 1 × 3mm for thighs, and field of view
= 520 × 320 × 200 mm and voxel size = 1.3 × 1.7 × 5 mm for
pelvis. This Dixon sequence follows a seven peak fat model-
ling and provides separate images for fat and water. The ac-
quisition time was 45 min per patient.
Three investigators (C.N-P., A.A-P, and J.D-M.) analysed the
Dixon MR images using a Philips Research Image Development
Environment tool developed for this project. Regions of
interests (ROIs) were manually drawn on four slices of the
following muscles: rectus femoris, vastus intermedius, vastus
lateralis, vastus medialis, adductor magnus, sartorius, gracilis,
semitendinosus, and semimembranosus; on three slices of
biceps femoris long head, biceps femoris short head, and
adductor longus; and on one slice for psoas and lumbar
paraspinal muscles. Slices covered the proximal, middle, and
distal part of the muscles. We used anatomical landmarks to
ensure consistency between annual analyses. For every ROI,
the total area and area covered by fat were calculated
automatically using the Philips Research Image Development
Environment tool. The fat fraction (FF) coefficient was defined
as fat/(fat + water), where fat and water were the image inten-
sity values over the ROI for the fat and water Dixon images, re-
spectively. From those two parameters, and assuming that
water content corresponds mainly to muscle, fat and muscle
areas were estimated. Cumulative values across all slices were
also computed, and as a final index, muscle FF was calculated
as follows: FF = (muscle fat area × 100)/muscle area. Once we
obtained the values from every muscle, we calculated the
thigh FF as follows: thigh FF = (sum of fat area of all thigh
muscles × 100)/sum of muscle area of all thigh muscles. For
every muscle, we calculated the muscle fatty transformation
rate = FF final visit  FF initial visit/(one-initial FF).
The time required to quantify FFs in Dixon images was 45 to
60 min per patient. A high degree of reliability was found be-
tween investigators. The Intraclass coefficient (ICC) coefficient
was 0.982, with a 95% confidence interval from 0.977 to 0.987.
Statistics
We confirmed that the variables were normally distributed
using a Kolmogorov–Smirnov test, and therefore, parametric
statistical studies were used. Longitudinal analysis of the
different outcome measures, including muscle function tests
and muscle FF quantified by MRI, was performed using linear
mixed models applying the Greenhouse–Geisser test. To
evaluate the magnitude of the changes observed in the re-
sults of outcome measures over the 3 year follow-up period,
we provide the standardized response mean (SRM). The SRM
is calculated by dividing the mean score change (final visit
minus initial visit) by the standard deviation of the change.
The estimation of the magnitude of change over time using
this formula is based on Cohen’s rule for effect size (ES):
‘trivial’ (ES < 0.20), ‘small’ (ES ≥ 0.20 <. 50), ‘moderate’ (ES
≥ 0.50 < 0.80), or large (ES ≥ 0.80).22
To study the influence of clinical and demographic factors
in the progression of skeletal muscle FFs, we performed a
two-step process. In the first exploratory step, we used a
Pearson test to analyse the correlation between every factor
of interest and the increase in thigh FF. Those factors with
both a statistically significant correlation and a correlation
coefficient higher than 0.4 were selected for the second step.
This second step consisted of an ANCOVA analysis in which
the influence of every selected factor on mean thigh FF
increase, as detected by MRI, was assessed separately. The
significance level for all statistical studies was set at p <
0.05, and post hoc Bonferroni corrections were used when
needed. Statistical studies were performed with SPSS for
Mac computers (Version 21, SPSS Inc, Chicago, IL). Heatmaps
were developed using R version 3.1.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
Description of the cohort
Thirty-six LOPD patients (20 women, 55.5%) were enrolled in
this study. Mean age at the start was 43.9 ± 14.8 years old.
Table 1 provides the main clinical data of the patients at visit
0 (baseline). At Visit 0, 23 patients were already being treated
with ERT with Myozyme® for a mean period of 4.1 years. All
these patients continued the treatment without interruptions
during the whole follow-up. Out of the 13 remaining patients,
four started treatment during the follow-up because of the
development of muscle weakness impairing the flexion
and/or extension of the hip, as demonstrated in clinical
examination. These four patients have been excluded from
the statistical studies, and their results are shown separately.
All these patients started treatment 1 to 3 months after Visit
1. The remaining nine patients were considered pre-
symptomatic because they did not report any relevant symp-
toms or had no muscle weakness found by clinical
examination, at any time during the study. At Visit 0, 10 pa-
tients needed walking aids such as a cane or a stick for walk-
ing outdoors, and 11 patients needed nocturnal non-invasive
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ventilation support (Table 1). During the follow-up period,
three patients started using walking aids, and two more
started using non-invasive ventilation at night.20
Functional assessments
The muscle function tests that showed significant differences
in symptomatic-treated patients after the follow-up period
were lower limb muscle strength, measured using MRC and
hand-held myometry, and respiratory muscle strength
(forced vital capacity seated), with p values lower than 0.01
and high SRMs as shown in Table 2. Specific details of the
myometry assessments are detailed in Table 3. In summary,
all myometry assessments of the lower limbs but knee flexion
showed worsening of muscle strength, with knee extension
and hip flexion being the two that worsened the most
(4.9 and 4.3 kg, respectively). In contrast, myometry as-
sessments of the upper limbs did not show significant
differences. We did not observe significant differences in
timed tests, MFM-20, or daily life activity scales after this pe-
riod of time. In the case of pre-symptomatic patients, we did
not observe significant differences in any of the results of the
motor function tests, spirometry, or daily life activity scales.
Quantitative muscle magnetic resonance imaging:
progression of fat fraction in late-onset Pompe
disease patients
We performed a total of four visits for the whole cohort of
patients using two-point Dixon. In every case, we calculated
the area of the muscle, the muscle fraction, and the FF of
psoas, paraspinal muscles, and each muscle in the thighs,
and from that, we derived the mean thigh FF. In the case of
symptomatic patients treated with Myozyme®, we observed
a statistically significant increase in mean thigh FF of 5.7 ±
3.7% at the end of the follow-up, which corresponds to an




















1 F 38 47 50 N N Y (stick) N
2 F 30 39 48 Y (stick, wheelchair) Yes (non-invasive) Y (fully wheelchair) Yes (non-invasive)
3 F — — 26 N N N N
4 F 49 59 63 Y (crouch) N Y (crouch) N
5 F 30 42 45 N N N N
6 F 27 47 51 N N N N
7 M 62 67 66 N Y (non-invasive) N Y (non-invasive)
8 F 48 52 59 Y (stick) N Y (stick) Y (non-invasive)
9 F 40 48 55 N N N N
10 M 36 39 42 N Y (non-invasive) N Y (non-invasive)
11 F 15 24 31 Y (Walker, wheelchair) Y (non-invasive) Y (Walker, wheelchair) Y (non-invasive)
12 F 27 39 46 N N N N
13 M 35 45 47 N Y (non-invasive) N Y (non-invasive)
14 M 41 45 51 N Y (non-invasive) N Y (non-invasive)
15 F 39 46 51 Y (crouch) Y (non-invasive) Y (crouch) Y (non-invasive)
16 M — — 22 N N N N
17 M — — 51 N N N N
18 M — — 14 N N N N
19 F 40 64 65 Y (stick) N Y (stick) N
20 F 24 29 35 Y (crouch) N Y (crouch) N
21 F 36 40 41 N Y (non-invasive) N Y (non-invasive)
22 F 14 45 52 N N Y (stick) N
23 M 22 57 64 Y (Stick) Y (non-invasive) Y (stick) Y (non-invasive)
24 M — — 8 N N N N
25 F 42 55 57 Y (Stick) Y (non-invasive) Y (stick) Y (non-invasive)
26 M 35 43 46 N Y (non-invasive) N Y (non-invasive)
27 M 34 51 51 N N N Y (non-invasive)
28 M — — 51 N N N N
29 M 32 43 44 N N N N
30 F 39 48 54 N N Y (stick) N
31 M — — 12 N N N N
32 M — — 51 N N N N
33 M 38 43 42 Y (stick) N Y (stick) N
34 F 20 22 21 N N N N
35 F — — 35 N N N N
36 F 24 40 29 N N N N
F, female; G, gender; M, male; N, not needed; P, patient number; Y, yes.
Follow-up of late-onset Pompe disease patients with muscle MRI 1035
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 1032–1046
DOI: 10.1002/jcsm.12555
increase of 1.9% per year (Greenhouse–Geiser test, p <
0.0001 and SRM 1.6) (Figure 1A). Increase in mean thigh FF
varied substantially from one patient to another, with a max-
imum of +13.2% and a minimum of +0.8% (Figure 1B). We ob-
served a significant increase in FF in all muscles analysed,
except the paraspinal muscle, as described in Table 4 and
displayed in Figure 2. An example of this increase can be
found in Figure 3.
In the case of pre-symptomatic patients, we observed a
statistically significant increase in mean thigh FF of 2.6 ±
1.6% at the end of the follow-up, which represents an in-
crease of 0.8% per year (Greenhouse–Geiser test, p <
0.0001) (Figure 1B). However, we identified higher values
of FF in the adductor major and the paraspinal muscles of
some pre-symptomatic patients at Visit 0, especially those
older than 25 (Figure 1D). In fact, we observed a positive
correlation between the age at study of pre-symptomatic
patients, and the percentage of FF in these two muscles
(adductor major: ρ = 0.71, p = 0.02; paraspinal muscles:
ρ = 0.96, p = 0.0001; Pearson test). On the basis of these
data, we decided to divide our cohort of pre-symptomatic
patients into younger than 25 years old at baseline (n = 5
patients) and older than 25 years old at baseline (n = 4
patients). Mean thigh FF did not change significantly in pre-
symptomatic patients younger than 25 (+0.7 ± 0.3% in 4
years; Greenhouse–Geisser p = 0.33), while it increased
significantly in patients older than 25 (+3.2 ± 0.4% in 4 years;
Greenhouse–Geisser p = 0.004).
Table 2 Change between Visits 0 and 3 evaluation in muscle function tests, spirometry, quantitative muscle magnetic resonance imaging, and patient
reported outcome measures in treated and pre-symptomatic late-onset Pompe disease patients
Test
Symptomatic treated patients n = 22 Pre-symptomatic patients n = 9
Visit 0 Visit 3 P SRM Visit 0 Visit 3 P SRM
Time to walk 10 m (s) 7.9 ± 3.8 7.8 ± 6.1 0.30 0.3 3.1 ± 0.5 2.8 ± 0.8 0.39 0.1
6MWT (m) 394.4 ± 150.4 422.3 ± 140.1 0.16 0.1 599.6 ± 85.4 596.2 ± 69.5 0.29 0.03
Timed up & go (s) 7.5 ± 7.2 10.2 ± 6.2 0.20 0.4 3.8 ± 1.5 4.1 ± 0.9 0.44 0.4
Time to climb up four stairs (s) 4.8 ± 3.5 4.7 ± 2.9 0.59 0.3 1.4 ± 0.3 1.3 ± 0.3 0.20 0.3
Time to go down four stairs (s) 3.6 ± 2.4 3.3 ± 2.1 0.40 0.3 1.3 ± 0.1 1.3 ± 0.2 0.61 0.3
MRC total score 95.5 ± 11.1 90.8 ± 11.8 0.0001 0.9 110 ± 0 110 ± 0 0.99 0
MRC LL score 47.1 ± 10.2 42.5 ± 10.3 0.001 0.8 60 ± 0 60 ± 0 0.99 0
Myometry total (kg) 203.7 ± 118.8 180.9 ± 107.7 0.005 0.6 312.3 ± 91.3 354.9 ± 82.3 0.21 0.2
Myometry LL (kg) 117.5 ± 67.7 97.3 ± 58.3 0.0001 0.8 172.3 ± 81.6 201.6 ± 47.0 0.35 0.3
Myometry UL (kg) 95.2 ± 50.4 91 ± 48.4 0.27 0.2 130 ± 10.2 145.8 ± 9.4 0.08 0.5
MFM20 score 48 ± 8 47.6 ± 8.7 0.32 0.1 59 ± 2.4 59 ± 1.9 0.66 0
FVC seated (L) 75.9 ± 22.9 69 ± 25.4 0.0001 0.8 93.6 ± 12.8 90.1 ± 10.3 0.48 0.2
FVC supine (L) 67.6 ± 25.3 65.7 ± 24.1 0.74 0.4 89.3 ± 17.6 88.3 ± 22.5 0.37 0.1
ACTIVLIM score 28 ± 7 27.7 ± 6.8 0.84 0.1 36 ± 0 36 ± 0 0.99 0
Mean thigh FF (%) 36.5 ± 18.6 42.31 ± 19.39 0.0001 1.6 11.9 ± 4.4 15.1 ± 5.1 0.01 1.2
Mean Ps FF (%) 81.8 ± 10.2 82.9 ± 8.6 0.32 0.3 38.3 ± 24.4 45.8 ± 24.3 0.26 0.6
Mean value and standard deviation are shown. Greenhouse–Geisser test analysing the data from Visits 1, 2 and 3 were used to find out
whether the differences observed were statistically significant.
ACTIVLIM, activity limitations; FF, fat fraction; FVC, forced vital capacity; LL, lower limbs; MFM20, Motor Function Measure 20-item scale;
MRC, Medical Research Council; Ps, paraspinal muscles; SRM, standardized response mean; UL, upper limbs; 6MWT, 6 min walking test.
Table 3 Change between Visits 0 and 3 evaluation in hand-held myometry assessments in symptomatic-treated and pre-symptomatic late-onset
Pompe disease patients
Test
Symptomatic treated patients n = 22 Pre-symptomatic patients n = 9
Visit 0 Visit 3 p SRM Visit 0 Visit 3 p SRM
Neck flexion 7.3 ± 5.3 8.1 ± 6.1 0.1 0.15 15.5 ± 5.7 15.1 ± 6.7 0.2 0.05
Shoulder abduction 23.2 ± 10.3 22.4 ± 10.2 0.52 0.12 27.6 ± 9.7 27.7 ± 6.7 0.98 0.01
Shoulder adduction 15.4 ± 10.3 16.2 ± 2.2 0.37 0.14 26.5 ± 8.7 29.9 ± 7.8 0.02 0.37
Elbow flexion 25.3 ± 12.1 22.9 ± 2.3 0.06 0.38 29.7 ± 9.4 37.4 ± 7.7 0.02 0.82
Elbow extension 19.2 ± 9.9 17.8 ± 8.2 0.13 0.34 24.2 ± 7.4 26.3 ± 6.2 0.22 0.41
Hip flexion 21.4 ± 13.8 17.1 ± 12.7 0.007 0.61 33.9 ± 11.9 32.5 ± 12.3 0.46 0.5
Hip extension 11.3 ± 9.1 8.7 ± 8.9 0.001 0.76 33.2 ± 25.1 35.1 ± 8.1 0.06 0.19
Hip abduction 18.3 ± 12.1 14.6 ± 10.9 0.005 0.63 33.4 ± 17.7 30.3 ± 10.7 0.46 0.24
Hip adduction 11.5 ± 7.3 8.8 ± 6.3 0.001 0.76 20.8 ± 6.3 19.8 ± 5.7 0.27 0.42
Knee extension 33.6 ± 19.8 28.7 ± 16.4 0.01 0.54 48.1 ± 15.7 47.1 ± 11.5 0.88 0.06
Knee flexion 20.1 ± 14.2 19.1 ± 11.4 0.31 0.18 35.2 ± 13.2 34.7 ± 8.2 0.91 0.04
Mean value and standard deviation are shown. Greenhouse–Geisser test analysing the data from Visits 1, 2, 3 and 4 was used to find out
whether the differences observed were statistically significant, and p values are shown. All units are expressed as kilogrammes.
SRM, standardized response mean.
Bold emphasis mean statistical significance
1036 C. Nuñez-Peralta et al.
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 1032–1046
DOI: 10.1002/jcsm.12555
Correlation between changes in muscle function
and fat fraction identified by magnetic resonance
imaging
We observed a significant correlation between increase in
mean thigh FF and changes in muscle strength as measured
by hand-held myometry and MRC, as shown in Table 5. The
strongest correlation was between increase in FF in the vasti
muscles and decrease in muscle strength for knee extension
(ρ = 0.54, p = 0.02). We also found significant correlations
between increase in mean thigh FF and the changes ob-
served in the following timed tests: time to walk 10 m, 6
min walking test, time to climb up four steps and time to
go down four steps (Table 5). In contrast, we did not identify
a significant correlation between increase in mean thigh FF
and results of the MFM-20 score or the activity limitations
test.
Analysis of patients who started treatment during
follow-up
A total of four patients started treatment with Myozyme®
during follow-up, because of the onset of muscle weakness.
Figure 1 (A) Increase in mean thigh fat fraction at year 1, year 2 and year 3 related to the baseline value. Red bars show data from symptomatic pa-
tients treated while blue bars show data from presymptomatic patients. Mean increase and standard error is provided. (B) Increase in mean thigh fat
fraction in every single patient of the cohort at visit 3 related to baseline. Red bars represent ERT treated patients. Blue bars represent presymptomatic
non-treated patients older than 25, and yellow bars represent patients younger than 25 years old. (C) Involvement of paraspinal and adductor major
muscles in presymptomatic patients depending on the age. Fat replacement and atrophy of both muscles was observed in patients older than 25 years
old. *Paraspinal muscles **Adductor major muscles
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Table 4 Increase in fat fraction described by each muscle analysed in treated and pre-symptomatic patients
Symptomatic treated patients (n = 23) Pre-symptomatic patients (n = 9)
Muscle Visit 0 FF Visit 3 FF P SRM Visit 0 FF Visit 3 FF P SRM
Rectus femoris 19.5 ± 18.7 21.1 ± 17.1 0.001 0.84 8.8 ± 2.6 11.3 ± 2.7 0.007 1.02
Vastus medialis 31.64 ± 26.9 31.35 ± 27.1 0.009 0.71 10.2 ± 2.2 12.3 ± 2.4 0.14 1.01
Vastus lateralis 22.6 ± 16.4 27.2 ± 21.1 0.0001 1.07 8.5 ± 1.8 12 ± 2.6 0.007 1.34
Vastus intermedius 38.7 ± 27.2 40.6 ± 28.5 0.0001 1.14 9.7 ± 3.1 14.3 ± 4.1 0.01 1.76
Biceps short head 28.3 ± 20.5 32.7 ± 21.5 0.07 1.18 12.8 ± 4.3 15.7 ± 4.2 0.33 0.61
Biceps long head 55.8 ± 29.1 64 ± 26 0.0001 0.96 11.8 ± 5.1 15.4 ± 7.2 0.03 2.91
Semimembranosus 66.7 ± 26.4 70 ± 24 0.02 0.63 16.9 ± 12.7 21.6 ± 14.5 0.69 0.47
Semitendinosus 46.7 ± 29.1 51.3 ± 32.8 0.0001 0.98 12 ± 4.2 14.2 ± 5.8 0.14 1.12
Adductor major 79.4 ± 17.2 79.2 ± 17.3 0.02 0.69 22.1 ± 20.1 27.2 ± 26.3 0.37 0.69
Adductor longus 51.7 ± 33.6 51.9 ± 32.5 0.0001 0.86 11 ± 3.2 14.8 ± 3.2 0.01 3.43
Sartorius 25.3 ± 17.6 27.8 ± 17 0.0001 0.89 19.8 ± 5.3 20.7 ± 5.5 0.49 0.02
Gracillis 22.8 ± 13 27 ± 12.9 0.0001 0.91 15.2 ± 3.8 17. 2 ± 4.4 0.27 0.4
Paraspinalis 80.4 ± 9.7 83.3 ± 6 0.29 0.3 38.3 ± 24.4 45.8 ± 24.3 0.26 0.6
Psoas 54.8 ± 30.6 60.6 ± 28.7 0.051 0.22 24.7 ± 16.2 29.2 ± 15.9 0.27 0.26
Total thighs 39.5 ± 18.2 42.6 ± 19 0.0001 1.69 12.1 ± 4.2 15.1 ± 5 0.0001 1.26
Mean fat fraction and standard deviation at Visits 0 (baseline) and 3 (Year 3) are provided. Linear mixed model applying Greenhouse–
Geisser test was performed, and p is provided. Bold numbers in p values are related with significant changes. The standardized response
mean (SRM) for every muscle is also provided.
FF, fat fraction.
Figure 2 Heatmaps showing changes in fat fraction of thigh muscles studied in symptomatic-treated late-onset Pompe disease patients. Patients and
muscles are ordered according to hierarchical clustering with increasing replacement severity from bottom to top (patient-rows) and from left to right
(muscles-columns). The increase in fat fraction over a 3 year period of time in the muscle of a patient is indicated by the colour of the square. Red
colours mean increased fat fraction, while blue colours mean decreased fat fraction.
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All cases started the treatment shortly after Visit 1 (1 to 3
months later). Table 6 shows the mean thigh FF at Visit 0
(baseline) and the changes observed at every visit in these
four patients. We identified a reduction in the rate of FF in-
crease between Visits 0 and 1 (before treatment was started,
mean increase +3.39%), Visits 1 and 2, and Visits 2 and 3
(both after starting the treatment, mean increase +1.52%
and +1.71% respectively). However, we did not apply any sta-
tistical tests to these data because they only correspond to
four patients and can therefore be considered merely de-
scriptive, requiring further evaluation.
Factors influencing increase in fat fraction
We analysed which demographic, clinical, and muscle-
functional factors could influence the progression of mean
thigh FF in Pompe disease patients. In a first step, we studied
which variables had a significant correlation with mean in-
crease in thigh FF, using Pearson correlation tests (Table 7).
After that, in a second step, we confirmed which of these var-
iables were influencing progression of FF using an ANCOVA
analysis. Table 8 shows the variables that correlated with
the progression of FF in our cohort of patients after this anal-
ysis, and Figure 4 displays the graphics showing correlations
between variables. We observed that at an earlier start of
the symptoms, a longer period of treatment, muscle function
at baseline, and muscle FF at baseline were associated with a
higher increase in FF in the muscle MRI.
Muscle fat fraction progression: recommendations
for the follow-up
We wanted to identify which muscles could be best for
following up fatty replacement in LOPD patients in clinical
Figure 3 Images illustrate the change in fat replacement throughout the follow-up. Fat fraction maps acquired from the thigh at Visits 0 and 3 (0–100%
scale). Increase in fat replacement was visible in most of the muscles, with changes most obvious in the following muscles: (A and A’) vastus lateralis (in
this patient fat fraction increased from 15.5% to 35.7%), (B and B’) long head of the biceps femoris (fat fraction increased from 57.6% to 79.4%), (C and
C’) semitendinosus (fat fraction rose from 20.3% to 51.4%), and (D and D’) semimembranosus (fat fraction increased from 74.2% to 82.4%).
Table 5 Correlation between increase in fat fraction during the follow-up
and changes observed in muscle function tests in late-onset Pompe dis-






Time to walk 10 m (s) 0.011 0.43
6MWT (m) 0.024 -0.48
Timed up & go (s) 0.09 0.32
Time to climb four stairs (s) 0.017 0.46
Time to go down four stairs
(s)
0.015 0.47
MRC LL score (kg) 0.31 0.15
Myometry LL (kg) 0.032 -0.4
MFM-20 (score) 0.56 -0.13
FVC seated (L) 0.023 -0.39
FVC supine (L) 0.20 -0.24
ACTIVLIM score 0.29 0.18
Correlation was studied using Pearson test. p value was considered
significant if lower than 0.05.
ACTIVLIM, activity limitations; FVC, forced vital capacity; LL, Lower
limbs; MFM20, Motor Function Measure 20-item scale; MRC, Med-
ical Research Council; 6 min walking test.
Bold emphasis means variables that were selected for the ANCOVA
study
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trials or natural history studies. Increase in FF in most of the
muscles analysed was statistically significant in symptomatic-
treated patients at the end of the follow-up period. How-
ever, we observed a high variability in the amount of in-
crease from one patient to another. In order to classify
patients in similar groups, we divided our cohort into four
groups, depending on the mean thigh FF at Visit 0 (baseline),
which we had previously described as correlating with the
clinical situation of the patient.23 Table 9 shows the four
groups and the changes observed in FF during the follow-
up. The first group was ‘baseline FF lower than 15%’. All indi-
viduals in that group (n = 9) were pre-symptomatic. Although
these patients had never had muscle weakness or any symp-
toms of muscle weakness, we already detected high values
of FF in the paraspinal muscles at baseline visit (FF = 35%).
In this group, the muscle with a higher progression was the
paraspinal muscles. The second group (15% to 30% baseline
mean thigh FF) included 11 symptomatic patients. In this
group, both paraspinal and adductor major were the two
muscles showing the highest values of FF at baseline
(78.8% and 75.3% respectively). The muscle with a more uni-
form progression was the long head of the biceps femoris
long head. The third group (31% to 45% baseline mean thigh
FF) included six individuals, all of whom were symptomatic.
In this group, paraspinal, adductor major, semimembranosus,
semitendinosus, and biceps femoris long head muscles were
replaced by fat to a large extent, and the muscles identified
with a higher increase in FF were the biceps femoris short
head, the vastus intermedius, and the vastus lateralis. The
last group (more than 45% baseline mean thigh FF) had 11
individuals, all of them symptomatic. In this group,
paraspinal, adductor major and longus, biceps femoris long
head, semimembranosus, semitendinosus, and psoas were
replaced by fat and therefore not useful for the follow-up.
In contrast, we identified vastus lateralis as the best candi-
date for the follow-up. A summary of all these findings is
displayed in Figure 5.
Table 7 Correlation between increase in fat fraction after 4 years of fol-







Sex (M/W) 0.43 0.15
Age at onset of symptoms
(year)
0.14 0.12
Time of progression (year) 0.049 0.34
Age at onset of ERT (year) 0.002 0.7
Time on ERT (year) 0.019 0.49
Antibody titers 0.87 0.05
Use of aids for walking (Yes/No) 0.31 0.15
Use of ventilation (Yes/No) 0.016 0.42
Time to walk 10 m (s) 0.06 0.37
6MWT (m) 0.005 0.52
Time to climb four steps (s) 0.004 0.53
Time to go down four steps (s) 0.07 0.35
Timed up & go test (s) 0.38 0.22
MFM20 (score) 0.002 0.57
MRC lower limbs (score) 0.0001 0.65
Myometry lower limbs (kg) 0.1 0.39
FVC (L) 0.73 0.15
ACTIVLIM (score) 0.65 0.16
Baseline mean thigh FF (%) 0.001 0.58
Correlation was studied using Pearson test. Antibody titers were
studied at baseline visit.
ACTIVLIM, activity limitations; ERT, enzymatic replacement ther-
apy; FVC, forced vital capacity; M, men; MFM20, Motor Function
Measure 20-item scale; MRC, Medical Research Council; 6 min
walking test; W, women.
Bold emphasis:patients with statistical significance
Table 8 A one-way analysis of covariance was conducted to determine
which factors influenced the progression of mean thighs fat fraction
Factor Effect on increase in FF
Time of progression 0.49
Age at onset of ERT 0.001
Time on ERT 0.045
Ventilation 0.56
Age at ventilation 0.007
Time to walk 10 m 0.052
6MWT 0.009
Time to climb four steps 0.004
Time to go down four steps 0.12
MRC lower limbs 0.0001
Myometry lower limbs 0.21
MFM20 0.001
Baseline FF 0.0001
Results of Greenhouse–Geisser test are shown and were considered
significant if p < 0.05.
ERT, enzymatic replacement therapy; FF, fat fraction; MFM20, Mo-
tor Function Measure 20-item scale; MRC, Medical Research Coun-
cil; 6 min walking test.
Bold emphasis: statistical significance
Table 6 Changes in mean thighs fat fraction observed in the four patients who started the treatment during the follow-up due to the presence of
muscle weakness
Patient
Mean thighs fat fraction
Visit 0 (%) Visit 1 (%) Visit 2 (%) Visit 3 (%)
Patient 1 25.26 30.66, +5.4 31.74, +1.08 32.25, +0.51
Patient 2 9.85 9.43, 0.42 9.02, -0,41 10.53, +1.51
Patient 3 57.69 62.11, +4.42 65.5, +3.39 67.93, +2.43
Patient 4 26.05 30.22, +4.17 32.27, +2,05 34.67, +2.4
Group +3.39 +1.52 +1.71
Mean thighs fat fraction and increase over previous visit is shown for every patient.
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Discussion
In this study, we followed-up a large cohort of patients with
LOPD, both symptomatic-treated and pre-symptomatic pa-
tients, for a period of 4 years using Dixon quantitative muscle
MRI and several clinical assessments including muscle func-
tion tests, spirometry, and activities of daily living scales.
We detected a significant and continuous increase in muscle
fat replacement in symptomatic patients despite being
treated with ERT, which correlated to a decrease in muscle
strength. In the case of pre-symptomatic patients, we identi-
fied an increase in FF, especially in paraspinal muscles, that
was not associated to any change in motor function tests.
The study has allowed us to confirm that quantitative muscle
MRI is able to identify subtle changes in muscle structure and
it can be considered a promising outcome measure for the
follow-up of patients in natural history studies or clinical
trials.
Late-onset Pompe disease is a metabolic disorder charac-
terized by a progressive accumulation of glycogen inside the
lysosomes of the tissues. The increasing number of
glycogen-charged lysosomes in the sarcoplasm of the muscle
fibres triggers a set of processes that eventually lead to mus-
cle fibre death and replacement by fat and fibrotic tissue.24,25
The loss of muscle fibres is related to the muscle weakness of
these patients. In recent years, quantitative muscle MRI has
been implemented as one of the best candidate biomarkers
to follow-up disease progression in patients with different
muscle disorders, such as Duchenne muscle dystrophy,
facio-scapulo-humeral muscle dystrophy, limb girdle muscle
dystrophy 2I, or Pompe disease.26–28 Most of the previously
published studies using qMRI have focused on quantifying
Figure 4 (A) Correlation between age at start of ERT and increase in mean thigh fat fraction. (B) Correlation between age at start of ventilation and
increase in mean thigh fat fraction. (C) Correlation between results of the 6 min walking test (6MWT) at baseline and increase in mean thigh fat frac-
tion. (D) Correlation between time to climb four steps at baseline and increase in mean thigh fat fraction. (E) Correlation between MRC for lower limbs
at baseline and increase in mean thigh fat fraction. (F) Correlation between mean thigh fat fraction at baseline and increase in mean thigh fat fraction.
ERT, enzymatic replacement therapy; MRC, magnetic resonance imaging.
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the amount of fat and/or water present in the skeletal
muscles of the patients. Two-point or three-point Dixon,
global T2, and 1H spectroscopy are the main techniques used
for this purpose.18 Here, we have used two-point Dixon,
which is a qMRI sequence that can be done in 1.5 Teslas
MRIs, available in most of the clinical centres that follow
Pompe patients. Our results support the use of Dixon
technique as a reliable outcome measure for the follow-up
of patients with LOPD disease. Using this technique, we have
shown that skeletal muscle FF increases in symptomatic
patients despite ongoing treatment with ERT.
The yearly progression ratio of mean FF, close to 2%, was
stable in our cohort. This increase is slightly higher than the
one found in previous studies. For example, the group of Pro-
fessor Carlier performed a retrospective analysis of 14 LOPD
patients treated with ERT and found a significant increase
of 0.9% in FF of all lower limb muscles during a 1 year pe-
riod.19 However, that study included lower leg muscles, such
as tibialis anterior or soleus, that are commonly less involved
in LOPD, probably reducing the final average increase in FF
observed. When comparing with other studies, it is important
to take into account the acquisition parameters used. For
example, in our Dixon sequence, we used a flip angle of 15°
that is higher than the one used in previous studies.19 A
higher T1 weighting, due to the use of a higher flip angle,
can lead to an overestimation of the FF, especially for higher
FF values.29 We have observed considerable variability in the
increase of FF from one patient to another, ranging from a
14% increase to less than 1%, suggesting that there are clini-
cal or genetic factors than can influence the progression of
the disease. We have observed that the following correlate
with a larger increase in FF over a 4 year period: (i) starting
ERT at a younger age, suggesting that patients started symp-
toms earlier; (ii) starting mechanical ventilation early; (iii)
worse baseline muscle performance; and (iv) higher baseline
fat replacement detected by MRI.
We have also detected significant changes in two function
tests: muscle strength and forced vital capacity. These results
are in line with other recently published evidence showing
decrease of muscle strength in LOPD patients despite ERT
treatment.12 Moreover, in our study, changes in muscle
strength is correlated with increase in FF, which has a clear
explanation. Increase in FF comes with a decrease in contrac-
tile muscle mass. It is therefore not unusual that those
patients in whom FF increased the most had a greater
decrease in muscle strength, as has been previously shown
in other muscle disorders such as limb-girdle muscular dystro-
phy type 2I.30 However, decrease in muscle strength did not
impact timed test results in our cohort of patients, probably
because these tests are not only influenced by muscle
strength, but also for other factors such as respiratory
involvement, fatigue, muscle pain, or personal motivation.
Quantification of FF using Dixon analysis can be a compli-
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No automatized software is yet available that can distinguish
one muscle from the others, and so the analysis has to be
performed manually.32 In this study, all MRIs were separately
analysed by three investigators with considerable experience
in this field. We have observed that if anatomical landmarks
are well established, the variability in the measurements be-
tween investigators is very low. Previous studies have shown
that fat replacement is not homogeneous in muscles in pa-
tients with muscle diseases, and therefore, analysing one
slice only is probably not sufficient to estimate the mean FF
of that muscle.33 It is therefore necessary to include several
slices of every muscle in the analysis, increasing significantly
the time needed to complete the study. The identification
of single muscles that could act as reporters of the increase
in FF is desirable because it could make studies more effi-
cient. Our study allows a description of the typical order in
which different muscles are involved, thereby sketching out
a hypothetical natural history of fat replacement progression.
In our opinion, this is an important step that should be made
to select the best muscle to identify changes in FF over a
period of time. If a muscle that has already been completely
replaced by fat is selected, no changes will be observed as
there is no more muscle to lose. On the other hand, if a
muscle that is not involved until very late in the progression
of the disease is selected, no changes will likely be recorded,
even though FF could actually be increasing in other muscles.
We have observed that paraspinal muscles are the first
muscles involved in LOPD from a radiological point of view,
probably leading to the frequently reported symptoms of
scoliosis in juvenile patients and lumbar pain or changes in
the walking pattern in adults.34,35 The adductor major muscle
is also involved early in the progression of the disease, and in
fact, we have observed that these two muscles are almost
completely replaced by fat in most of our symptomatic pa-
tients.36 The muscles of the posterior compartment of the
thighs are affected later, and so they can be considered good
candidates for monitoring FF progression during intermediate
stages of the disease. Finally, vasti muscles are involved in
more advanced cases. In fact, only two patients in our cohort
had clear quadriceps weakness leading to difficulties walking
downstairs or standing. Vastus lateralis is, in the light of our
results, a good candidate for monitoring FF progression in
patients that are at an advanced clinical stage.
We had the opportunity to study four patients before
and after starting ERT. Interestingly, we observed that ERT
decreased the rate of increase of FF from 3% to 1.7%, which
is a value close to the mean observed in the whole cohort,
suggesting that ERT with Myozyme® is effective in slowing
down the progression of muscle degeneration in Pompe dis-
ease. These results are in accordance with those previously
reported by the group of Professor Carlier. This group re-
ported that increase in FF was lower in patients treated
with ERT than in those not treated after 1 year of follow-
up (19).
Through our study, we realized that Dixon has some clear
limitations in the study of pre-symptomatic Pompe patients.
Increase in mean thigh FF was only significant in those pre-
symptomatic patients older than 25 years old but not in the
Figure 5 Progression of fat fraction depending on the baseline mean thigh fat fraction. (A) Baseline image showing the localization of thigh muscles
(VL: vastus lateralis, RF: rectus Femoris, VM: vastus medialis, VI: vastus intermedius, BFSH: biceps femoris short head, BFLH: biceps femoris long head,
ST: semitendinosus, SM: semimembranosus, AM: adductor major, AL: adductor longus, Sa: sartorius, and Gra: gracilis). (B) Increase in fat fraction over a
4 year period in patients with baseline mean thigh fat fraction of 15% to 30%. (C) Increase in fat fraction over a 4 year period in patients with baseline
mean thigh fat fraction of 30% to 45%. (D) Increase in fat fraction over a 4 year period in patients with baseline mean thigh fat fraction >45%. FF, fat
fraction.
Follow-up of late-onset Pompe disease patients with muscle MRI 1043
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 1032–1046
DOI: 10.1002/jcsm.12555
younger patients whose age ranged from 8 to 21 years old.
This can be related to the fact that the process of muscle de-
generation and fatty replacement was not active in younger
patients. However, we identified two different situations that
should be discussed and analysed in further studies. We al-
ready identified fat replacement in paraspinal and adductor
major muscles of some pre-symptomatic patients at baseline
visit, suggesting that the process of muscle degeneration pro-
gresses very slowly in Pompe, and is subclinical in some pa-
tients, until a moment in which patients experience muscle
weakness. However, we identified two young patients that
developed muscle weakness, one during the study, and the
other just at the end, in which increase in FF was not
detected despite those patients complaining of worsening
muscle weakness. In the first case, we observed mild psoas
and glutei weakness in a 19-year-old girl. At that moment,
her MRI did not show muscle fat replacement. The second
case was a 12-year-old boy who developed scoliosis and
glutei weakness 6 months after Visit 3 (end of the study).
We performed a new MRI that did not show muscle fat
replacement. It is therefore probable that in some cases,
the accumulation of glycogen-charged lysosomes, or the
presence of free glycogen in the sarcoplasm, disrupts muscle
fibre contraction, leading to muscle weakness before induc-
ing necrosis of the fibre and fatty substitution.37 In these
cases, Dixon may not be useful, because there are no
changes in fat tissue content. Therefore, a combination of
Dixon with a muscle MRI sequence able to identify glycogen
in the muscle fibres of weak muscles may more informative
in this subset of patients. Muscle glycogen can be identified
and quantified using some specific muscle MRI sequences,
such as GlycoCEST or (13)C-MR spectroscopy, but this tech-
nology is not routinely available on standard clinical scan-
ners.38,39 An increased signal intensity in Short Tau
Inversion Recovery (STIR) sequence in muscles from LOPD pa-
tients has been described, suggesting that this is related to
the presence of water molecules retained by glycogen.40 In
a similar way, increase in the water T2 signal in some muscles
was identified in LOPD patients, which correlated with a
higher increase in FF after 1 year follow-up, suggesting that
water T2 could be a potential marker of disease activity.19
However, increased signal intensity in STIR or changes in wa-
ter T2 is not specific and can be observed in muscle fibre ne-
crosis, inflammation, or denervation.41 In our opinion, for
Pompe patients, studying MRI sequences that are able to
identify changes related to the accumulation of glycogen is
likely to be especially useful for the study of juvenile patients
who are experiencing muscle symptoms.
Our results support the use of muscle MRI in the decision-
making process in patients with Pompe disease. We have
shown that a high value in FF in skeletal muscles at baseline
is associated with a quicker progression of the disease.
Moreover, there is a correlation between increase in FF and
changes in muscle function tests, which translates the clinical
importance of the radiological findings. As fat replacement is
an irreversible process, we suggest that muscle MRI should
be part of the initial assessment of patients with LOPD and
taken into account in deciding when to start treatment in
pauci-symptomatic patients.
To conclude, the results of our longitudinal study (i)
establish the rate of annual progression of fat replacement
in LOPD patients treated with ERT with Myozyme; (ii)
pinpoint clinical factors influencing the increase in muscle
FF; and (iii) show the clinical relevance of the changes ob-
served in muscle MRI.
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